Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul-Aug;73(4):511-515.
doi: 10.1016/j.ihj.2021.05.002. Epub 2021 Jun 8.

Susceptibility of CTLA-4 -1661A/G polymorphism towards severity of rheumatic heart disease

Ankit Bansal  1 , Sana Tasnim  2 , Mohit D Gupta  3 , Girish Mp  1 , Vishal Batra  1 , Samantha Kohli  2 , Sanjay Tyagi  1 , M A Qadar Pasha  2
Affiliations

Susceptibility of CTLA-4 -1661A/G polymorphism towards severity of rheumatic heart disease

Ankit Bansal et al. Indian Heart J. 2021 Jul-Aug.

Abstract

Aim: Genetic contribution in acute rheumatic fever (ARF)/rheumatic heart disease (RHD) has been suggested but not according to severity of the valve involvement. This study attempts to identify the relevance of CTLA-4 polymorphism with severity of the disease.

Methods: In a case-control design, 291 healthy controls and 83 patients were genotyped for association between RHD and single-nucleotide polymorphisms -1661A/G of CTLA-4.

Results: Segregation of patients on the basis of severity i.e., MVL (Mitral Valve Lesion) and CVL (Combined Valve Lesion) revealed that the frequency of CTLA-4 -1661G allele depleted as the disease progressed to CVL (p < 0.05). Patients in the age group of 31-45 years were significantly more susceptible (p < 0.046). Whereas, female patients were more susceptible than the male patients.

Conclusion: Our study suggests the risk associated with decreased frequency of CTLA-4 -1661G allele in the CVL group and in females.

Keywords: Acute rheumatic fever; CTLA-4; Polymorphism; Rheumatic heart disease; Valve lesions.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All the authors state that they have no conflict interest to declare with respect to the present article titled “Susceptibility of CTLA-4 −1661A/G polymorphism towards severity of Rheumatic Heart Disease”.

References

    1. Duzgun N., Duman T., Haydardedeoglu F.E., Tutkak H. Cytotoxic T lymphocyte-associated antigen-4 polymorphism in patients with rheumatic heart disease. Tissue Antigens. 2009;74:539–542. - PubMed
    1. Makrexeni Z.M., Pepeta L. Cardiovascular Topics Clinical presentation and outcomes of patients with acute rheumatic fever and rheumatic heart disease seen at a tertiary hospital setting in Port Elizabeth, South Africa. Cardiovasc J Afr. 2017;28:248–250. - PMC - PubMed
    1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–694. - PubMed
    1. Guilherme L., Kohler K.F., Kalil J. Rheumatic heart disease: genes, inflammation and autoimmunity. Rheumatol Curr Res. 2012 S4:001.
    1. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet. 2005;366:155–168. - PubMed